HANSOH PHARMA (03692): Almonertinib Marketing Authorization Receives Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
HANSOH PHARMA (03692) announced that on November 12, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for almonertinib for the treatment of non-small cell lung cancer.
Related Articles

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.
GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.






